Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 91.63% is 455% above its 5-year average of -25.82%, near the high end of its 5-year range (-255.52%–100.00%).
171.02% above its 12-month average of 33.81%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
91.63%
GROSS MARGIN AVG TTM
33.81%
GROSS MARGIN AVG 3Y
45.00%
GROSS MARGIN AVG 5Y
-25.82%
GROSS MARGIN AVG 10Y
-35.93%
GROSS MARGIN AVG 15Y
-55.64%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+171.02%
CURRENT VS 3Y AVG
+103.64%
CURRENT VS 5Y AVG
+454.89%
CURRENT VS 10Y AVG
+355.00%
CURRENT VS 15Y AVG
+264.68%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+122.38%
vs the sector median at left
Market Cap
$1.81B
Gross Margin
72.90%
TTM Avg
70.08%
3Y Avg
67.68%
5Y Avg
66.96%
Market Cap
$1.83B
Gross Margin
58.56%
TTM Avg
71.56%
3Y Avg
79.01%
5Y Avg
81.74%
Market Cap
$1.83B
Gross Margin
9.22%
TTM Avg
11.32%
3Y Avg
13.89%
5Y Avg
14.07%
Market Cap
$1.84B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
22.32%
5Y Avg
30.29%
Market Cap
$1.77B
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$1.75B
Gross Margin
21.37%
TTM Avg
23.53%
3Y Avg
23.33%
5Y Avg
22.63%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Xencor, Inc. (XNCR) | $1.81B | 91.63% | 33.81% | 45.00% | -25.82% |
| LeMaitre Vascular, Inc. (LMAT)vs › | $1.81B | 72.90% | 70.08% | 67.68% | 66.96% |
| Azenta, Inc. (AZTA)vs › | $1.81B | 44.05% | 44.96% | 41.63% | 40.93% |
| Sarepta Therapeutics, Inc. (SRPT)vs › | $1.83B | 58.56% | 71.56% | 79.01% | 81.74% |
| Astrana Health, Inc. (ASTH)vs › | $1.83B | 9.22% | 11.32% | 13.89% | 14.07% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | 0.00% | 0.00% | 22.32% | 30.29% |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | 100.00% | 100.00% | 100.00% | 100.00% |
| Immunome, Inc. (IMNM)vs › | $1.85B | 57.43% | 78.72% | 64.36% | 42.91% |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | 21.37% | 23.53% | 23.33% | 22.63% |
| Novavax, Inc. (NVAX)vs › | $1.86B | 93.67% | 81.97% | 61.43% | 74.28% |
Gross Margin
91.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 43.16% |
| 2025-12-31 | 90.87% |
| 2025-09-30 | -158.90% |
| 2025-06-30 | 93.92% |
| 2025-03-31 | 91.77% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | -227.19% |
| 2024-06-30 | 82.17% |
| 2024-03-31 | -255.52% |
| 2023-12-31 | 93.67% |
| 2023-09-30 | -9.76% |
| 2023-06-30 | -31.93% |
| 2023-03-31 | -245.70% |
| 2022-12-31 | -138.09% |
| 2022-09-30 | -95.15% |
| 2022-06-30 | -56.04% |
| 2022-03-31 | 44.14% |
| 2021-12-31 | 66.89% |
| 2021-09-30 | -157.13% |
| 2021-06-30 | 26.61% |
| 2021-03-31 | -21.92% |
| 2020-12-31 | -14.56% |
| 2020-09-30 | -25.69% |
| 2020-06-30 | -232.02% |
| 2020-03-31 | -4.81% |
| 2019-12-31 | -677.59% |
| 2019-09-30 | -36.81% |
| 2019-06-30 | -70.90% |
| 2019-03-31 | 74.82% |
| 2018-12-31 | -134.61% |
| 2018-09-30 | 27.85% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 99.99% |
| 2017-09-30 | -173.74% |
| 2017-06-30 | -26.83% |
| 2017-03-31 | -246.73% |
| 2016-12-31 | -107.45% |
| 2016-09-30 | -79.89% |
| 2016-06-30 | 78.17% |
| 2016-03-31 | -38.38% |
| 2015-12-31 | 50.00% |
| 2015-09-30 | -202.08% |
| 2015-06-30 | -637.28% |
| 2015-03-31 | -249.09% |
| 2014-12-31 | 10.81% |
| 2014-09-30 | -484.08% |
| 2014-06-30 | -419.78% |
| 2014-03-31 | -93.59% |
| 2013-12-31 | -137.56% |
| 2013-09-30 | -31.66% |
| 2013-06-30 | -5.43% |
| 2013-03-31 | -239.03% |
| 2012-12-31 | -62.60% |
| 2012-09-30 | -93.27% |
